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Regional brain morphology has a complex genetic architecture, consisting of many common
polymorphisms with small individual effects. This has proven challenging for genome-wide
association studies (GWAS). Due to the distributed nature of genetic signal across brain
regions, multivariate analysis of regional measures may enhance discovery of genetic var-
iants. Current multivariate approaches to GWAS are ill-suited for complex, large-scale data of
this kind. Here, we introduce the Multivariate Omnibus Statistical Test (MOSTest), with an
efficient computational design enabling rapid and reliable inference, and apply it to 171
regional brain morphology measures from 26,502 UK Biobank participants. At the conven-
tional genome-wide significance threshold of α= 5 × 10−8, MOSTest identifies 347 genomic
loci associated with regional brain morphology, more than any previous study, improving
upon the discovery of established GWAS approaches more than threefold. Our findings
implicate more than 5% of all protein-coding genes and provide evidence for gene sets
involved in neuron development and differentiation.
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Regional surface area and thickness of the cerebral cortex,and volume of subcortical structures, are highly heritablebrain morphological features with complex genetic archi-
tectures, involving many common genetic variants with small
effect sizes1,2. The predominant strategy for identifying genomic
loci associated with complex traits is through genome-wide
association studies (GWAS), a mass-univariate approach whereby
the association between a single outcome measure and each of
millions of genetic variants, in isolation, is tested. This is
accompanied by a stringent multiple comparison correction to
control the family-wise error rate, necessitating very large sample
sizes to identify even relatively strong effects. To date, the largest
GWAS of regional brain morphological features, based on brain
scans obtained from up to 50,000 individuals, identified almost
200 genetic variants1, which together explained only a fraction of
the reported narrow-sense heritability. These studies primarily
investigate each region of interest individually, compounding the
multiple-comparisons correction problem.
In addition to small effect sizes across many variants, the
genetic architectures of sets of regional brain features are likely to
strongly overlap. Gene expression studies of the human brain
have shown widespread gradients across the cortex3. Thus,
genetic variants probably have distributed effects across regions
and morphological measures. We have shown that cortical
thickness and surface area have extensive genetic overlap4, despite
reports that they are phenotypically and genetically only weakly
correlated to each other5, due to mixed directions of effects of the
underlying genetic variants4,6. The discovery of these variants
may be boosted through joint analysis of these traits in a multi-
variate framework. This avoids the family-wise error rate penalty
for studying multiple outcome measures, or the use of strategies
that reduce phenotypic information to a single composite score,
which can cause considerable loss of statistical power7. Impor-
tantly, a multivariate approach is much more consistent with the
notion of the brain being an integrated unit, with highly inter-
connected and biologically similar brain regions, compared to
univariate approaches that ignore the information shared across
these component measures.
Several multivariate approaches to GWAS have been proposed
to date8,9. In this context, multivariate association at a given
single-nucleotide polymorphism (SNP) means that at least one of
multiple traits being considered is associated with the genotype
vector of that SNP9. To test for multivariate association, MQFAM
(also known as MV-PLINK)10 and MultiPhen11 both perform a
multiple regression whereby the genotype vector is used as an
outcome variable, while each phenotype is turned into an
explanatory variable; the p-value is then calculated from an F-test,
which tests for an association between the genotype vector and
the most predictive linear combination of phenotypes at each
SNP. The advantage of MultiPhen is that it uses ordinal regres-
sion, whereas MQFAM is based on canonical correlation analysis,
which in theory is less appropriate for prediction of a categorical
variable such as 0-1-2 coded genotype vector. The statistical
power of both methods is known to be similar to MANOVA8.
MultiABEL is another multivariate GWAS approach, which
implements Pillai’s trace MANOVA12 to calculate multivariate p-
value from summary statistics; its authors further advocate the
importance of rank-based inverse-normal transformation. Most
recently, aMAT13 was introduced. This test, based on a chi-square
test statistic, explores regularization (spectral filtering) of the
correlation matrix R as a way to further boost statistical power in
multivariate methods. Distinct from these multivariate tests of
association is the multi-trait analysis of GWAS (MTAG)
method14, which boosts discovery in a primary trait by con-
ditioning on one or more secondary traits and therefore does not
test the multivariate null hypothesis that none of the traits are
associated with a given SNP. Although all multivariate methods
listed above have been shown to substantially increase gene dis-
covery compared to univariate approaches8, they have not been
widely adopted by large-scale international consortia. This may
be due to that fact that the results can be less straightforward to
interpret, in addition to high computational costs, lack of user
friendliness, lack of method validation, and/or model assump-
tions not fitting with the real data.
Here we introduce the Multivariate Omnibus Statistical Test
(MOSTest), designed to boost the statistical power of imaging
genetics by capitalizing on the distributed nature of genetic
influences across brain regions and pleiotropy across imaging
modalities. MOSTest is efficient and capable of combining large-
scale genome-wide analyses of dozens of measures for tens of
thousands of individuals within hours while achieving enhanced
statistical power. Key steps of the MOSTest analysis include: (1)
applying a rank-based inverse-normal transformation to the
input measures; (2) estimating the multivariate correlation
structure from the GWAS on randomly permuted genotype data;
(3) calculating the Mahalanobis norm, as the sum of squared de-
correlated z-values across univariate GWAS summary statistics,
to integrate effects across the measures into a multivariate test
statistic; and (4) employing the gamma cumulative density
function to fit an analytic form for the null distribution, enabling
extrapolation to and beyond the 5 × 10−8 significance threshold.
The “Methods” section contains a detailed description of these
steps. We further provide extensive simulations of MOSTest
performance under a wide range of conditions to validate its
assumptions and compare it to other multivariate approaches.
We compare MOSTest with an established inferential metho-
dology recently used by the Enhancing NeuroImaging Genetics
through Meta-Analysis (ENIGMA) consortium1, referred to as
the min-P approach; this approach takes the smallest p-value of
each SNP across multiple univariate GWAS, and corrects this for
the effective number of traits studied11,15, i.e., shared genetic
architecture across traits does not contribute to statistical power.
Min-P achieves its maximum power when the genetic effects
across traits are independent; conversely, multivariate approaches
have greater power when genetic effects are shared across traits8.
We applied MOSTest to sets of regional brain morphology
measures, hypothesizing that it will outperform the min-P
approach due to the distributed nature of genetic effects and
the presence of pleiotropy across modalities. We find that
MOSTest improves locus discovery compared to min-P more
than threefold, doubling the effective sample size, with significant
loci having effects across regions and across feature subsets.
Further, through simulations, we confirm that MOSTest main-
tains correct type-I error in a range of scenarios. We conclude
that, due to the distributed nature of the genetic signal across
brain regions, joint analysis of regional morphology measures in a
multivariate statistical framework provides a way to enhance
discovery of genetic variants with current sample sizes.
Results
Locus discovery. Through MOSTest, we identified thousands of
independent SNPs reaching the genome-wide significance
threshold of α= 5 × 10−8 across hundreds of independent loci, as
shown in Fig. 1a. Overall, MOSTest led to a threefold higher
discovery than the min-P approach. The difference in perfor-
mance is particularly pronounced when all features are combined,
as is also evident from the Miami plots shown in Fig. 1b–e. For all
features combined, 92 loci were discovered by both MOSTest and
min-P, 20 were unique to min-P, and 255 were only discovered
by MOSTest. Supplementary Data 1–3 lists these loci, together
with for how many and which regions the lead SNPs were
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significant. Generally, loci discovered by both tests had significant
effects on multiple regions, loci discovered only by min-P had
effects on 1 or 2 regions, and loci discovered only by MOSTest
often had no whole-genome significant effect on any of the
regions.
As can be seen in Fig. 1f, many loci identified with MOSTest
were shared across the three feature subsets. Further, the number
of MOSTest-discovered loci for all features combined (347) is
larger than the summation of number of unique loci found when
analyzing these feature subsets individually (301). This illustrates
how MOSTest capitalizes on the distributed and non-sparse
nature of genetic effects through the combination of features.
Replication. We carried out replication analyses of the GWAS






















































































































Fig. 1 MOSTest improves locus discovery. a Number of independent genome-wide significant loci identified (on the y axis and in the bubbles) for each set
of features (on the x axis), by MOSTest (in darker colored circles) and by min-P (in lighter colored squares). b–e Miami plots, contrasting the observed
−log10(p-values), shown on the y axis, of each SNP for MOSTest (top half) with min-P (bottom half), for each of the feature sets. The x axis shows the
relative genomic location, grouped by chromosome, and the red dashed lines indicate the genome-wide significance threshold of 5 × 10−8. Note, y axis is
clipped at −log10(p-value)= 100. f Venn diagram depicting the number of loci, identified with MOSTest, overlapping between the three feature subsets.
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data were released after we carried out our primary analyses. The
loci discovered through MOSTest and min-P replicated at similar
levels, with ~40% being significant in this smaller additional sample
(Table 1). Therefore, the absolute number of loci replicating is three
times higher for MOSTest compared to min-P. Supplementary
Data 1–3 also lists the replication p-values by both min-P and
MOSTest per discovered locus.
Power. Using the MiXeR tool6,16, we fitted a Gaussian mixture
model of the null and non-null effects to the GWAS summary
statistics, estimating for each feature set the number of SNPs
involved, i.e., their combined polygenicity, and their effect size
variance, or “discoverability”. Please see the “Methods” section
for more details. The results are summarized in Fig. 2, depicting
the estimated proportion of genetic variance explained by dis-
covered SNPs by both approaches as a function of sample size.
The horizontal shift of the curve indicates that the effective
sample size of MOSTest is generally about twice as high as that of
min-P, with the highest discovery for MOSTest when all features
are combined, and lowest discovery for the set of cortical thick-
ness features.
Validation and comparison between MOSTest and other tools.
We performed extensive validation of MOSTest methodology and
implementation, checking its performance under a range of
conditions through simulations with synthetic data, and com-
paring this with other multivariate approaches besides min-P,
namely MultiABEL, MultiPhen, and MQFAM. We used a fra-
mework whereby effects are simulated on chromosome 21 to
compute statistical power, while all other chromosomes are kept
free of genetic signal to estimate type-I error under the null.
Supplementary Tables 4 and 5 list the full set of simulation sce-
narios, such as varying the sparsity of genetic effects and the
number of features included, as well as the heritability of these
features and their correlation structure. Further details about the
simulation framework are provided in the “Methods” section.
Under a range of conditions, all methods showed similar
statistical power, except for min-P with lower power. The methods
all maintained correct type-I equally well under the null and
following permutation, under these conditions, as summarized in
Supplementary Figures 1 and 2. However, we could not explicitly
validate type-I error for MultiPhen and MQFAM across the
genome due to slow runtime; these typically exceeded one hour to
calculate p-values per M= 100 variants in the power analyses, for
each one of 760 simulation runs. Therefore, it was impractical to
run these tests for M= 7.3 million causal variants. See Supple-
mentary Table 5 for the runtimes per simulation.
The min-P approach outperformed the multivariate methods
under one specific condition: when a small set of heritable
features are analyzed together with a much larger set of non-
heritable features (Supplementary Fig. 3). All tests have similar
power when all features are heritable, but do not share genetic
variants, or when shared genetic effect sizes follow a heavy-tailed
distribution (Supplementary Fig. 4).
The simulations revealed the importance of the rank-based
inverse-normal transformation: without this transformation, the
tests had inflated type-I error, as well as lower statistical power,
when the features were not normally distributed (Supplementary
Fig. 5). We note that an incorrect type-I error fully prohibits
an application of a statistical test. The MOSTest genotype
Table 1 Equal replication rates of genome-wide significant
loci by MOSTest and min-P.






MOSTest All 347 122 0.35
MOSTest Subcortical 177 68 0.38




min-P All 115 48 0.42
min-P Subcortical 90 40 0.44




Results from the replication of the genome-wide significant loci are identified through MOSTest
and min-P in an additional sample of 4884 individuals. The column “# loci replicated” indicates
the amount of discovered loci in the main analysis that surpass a nominal significance (p=
0.05) in the replication sample. The “fraction replicated” column divides the number of loci
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Fig. 2 MOSTest increases effective sample size. Estimated percent of genetic variance explained by SNPs surpassing the genome-wide significance
threshold, on the y axis, as a function of sample size, depicted on the x axis on a log10 scale, for each of the feature sets and for both MOSTest and min-P
methods. Percentages of genetic variance explained by discovered SNPs with current sample size (N= 26,502) are shown in parentheses.
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Fig. 3 The genetic variants identified with MOSTest have distributed effects across the cortex. Z-values from the univariate GWAS for each cortical
region for the two most significant lead SNPs from MOSTest applied to all features combined (left two columns for rs1080066 on chromosome 15, and
right two columns for rs13107325 on chromosome 4). The top two rows show the effects of the SNPs on regional surface area, and the bottom two on
cortical thickness. Positive effects of carrying the minor allele are shown in red, and negative in blue. Note: the absolute Z-value scaling is clipped at 8 (p=







































Regulation of cell differentiation
Regulation of cell development
Cell development
Embryo development
Cell morphogenesis involved in differentiation
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Regulation of multicellular organismal development
Negative regulation of cell differentiation
Negative regulation of neuron differentiation
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b
Fig. 4 Functional mapping and annotation indicates high neurobiological relevance. a Number of genome-wide significant genes identified (on the y axis
and in the bubbles) for each set of features (on the x axis), by MOSTest (in darker colored circles) and by min-P (in lighter colored squares). b Results from
the gene-set analyses following the application of MOSTest and min-P on all brain features. The 15 most significant Gene Ontology sets for MOSTest are
listed on the y axis and −log10(p-values) are shown on the x axis. Multiple-comparisons corrected MOSTest gene-set p-values are indicated by black
circles, min-P in gray squares.
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permutation scheme, absent in other tools, effectively captures
this issue, therefore forms an important part of the test that
prevents reporting inflated p-values and spurious associations.
Further, Supplementary Fig. 5 shows the role of covariance
structure across genetic effects, and across features. We observe
that the highest power to detect associations occurs when features
have realistic covariance structure, but genetic effects are not
correlated.
Our simulations further show that spectral regularization,
implemented only in MOSTest, is essential when there is linear
dependence between features. Regularization was not necessary in
our main analysis, as the conditioning number of phenotypic
correlation matrix R was reasonably low (Supplementary Table 4),
leading to a well-defined matrix R−1. However, in the presence of
linear dependence, MOSTest has invalid type-I error without
spectral regularization, while correct regularization solves this
issue and at the same time improves statistical power (Supple-
mentary Fig. 6). Further, Supplementary Fig. 6 shows that
estimation of phenotype covariance matrix can be done either
from the phenotypes themselves or from z-scores under
permutation, and that these two approaches yield nearly identical
results in the simulation scenarios. Note that the permutation
scheme has the advantage of not requiring availability of all
phenotypes at one site, allowing for application in a meta-
analytical setting.
Please see the “Methods” section and Supplementary Informa-
tion for further validation data, including Supplementary Fig. 7,
displaying scaled-down version of the simulations, and Supple-
mentary Fig. 8, QQ plots showing that the MiXeR model correctly
captures the LD dependence of the MOSTest association
statistics. We also performed LD score regression and used the
intercept as an indicator that MOSTest results are free of genomic
inflation (Supplementary Table 6). Note that the LD score
regression results should be interpreted with care17, and that we
have not provided formal proof that MOSTest p-values scales
with LD structure as required by LD score regression model.
Regional effects. Cortical maps, depicting the morphological
associations of the lead SNPs identified with MOSTest on all
features with regional surface area and thickness measures, made
clear that these SNPs have distributed effects, often with mixed
directions, across regions and feature sets. As an example, Fig. 3
shows the maps for the top two hits (rs1080066 on chromosome
15, p= 1.2 × 10−305, and rs13107325 on chromosome 4, p=
3.1 × 10−124); all other maps are provided in the Supplementary
Data. These maps revealed anterior-posterior gradients as well as
hemisphere-specific effects of some of the lead SNPs, in line with
previously reported genetic patterns of developmental regionali-
zation in the brain18,19.
Gene-level analyses, using Multi-marker Analysis of GenoMic
Annotation (MAGMA)20,21, indicated that 1034 out of all 18,775
protein-coding genes (i.e., 5.5%) were significant, with a p-value
below a Bonferroni-corrected threshold of α= 0.05/18,775.
Figure 4a shows the number of significant genes for each set of
features. Through competitive gene-set analyses, we identified
136 significant Gene Ontology sets for MOSTest applied to all
features, the vast majority of which related to neuronal
development and differentiation, with Fig. 4b listing the top 15.
Please see Supplementary Fig. 9 for the overlap between these
pathways, and Supplementary Data 12 and 13 for further
information on all significant genes and genetic pathways.
Discussion
Applying the MOSTest approach to structural brain imaging
data, we discovered more loci associated with regional cortical
and subcortical morphology than any previous GWAS of brain
morphology, even those that had nearly double the sample size1,2.
Further, a direct comparison with the established min-P method
in the same sample revealed a threefold increase in discovery.
This improvement indicates the presence of extensive shared
genetic architecture across brain regions and across morpholo-
gical measures, attesting to the importance of estimating levels of
polygenic overlap beyond those indicated by genetic correlations4,6,
and arguing for techniques that boost discovery of genetic deter-
minants leveraging shared signal between traits22. Indeed, over-
lapping genetic determinants are to be expected given the shared
genetic control of neurodevelopment across brain regions23, and
that similar molecular mechanisms operate across regional borders
defined by gross morphological features. This is in accordance with
the high levels of pleiotropy across many brain-related traits and
disorders24. Therefore, our multivariate strategy is better tailored
to the underlying neurobiological processes than conventional
univariate approaches, as confirmed by our identification of
highly significant links to gene sets of neuronal development and
differentiation.
Our extensive validation of the MOSTest methodology and
implementation show that the MOSTest is a valid statistical test
with good statistical power to detect associations in a multivariate
context, across a wide range of conditions, suitable for applica-
tions to large-scale data with many outcome measures. Key
advantages of MOSTest include (1) an orders of magnitude
shorter runtime as compared to MQFAM and MultiPhen, (2) a
built-in genotype permutation scheme that allows detection of
cases of invalid type-I error, (3) the ability to incorporate spectral
regularization of the phenotype matrix, and (4) extensive vali-
dation in simulations.
Our simulations showed that in some scenarios min-P out-
performs the multivariate methods, specifically when genetic
signal is sparse across phenotypes. As the level of sparsity will be
different across SNPs, it is expected that min-P may discover a
few additional SNPs that are missed by MOSTest, as also indi-
cated in our comparison using real data. Further, these simula-
tions made clear it is important to exclude traits with too low
heritability to achieve best possible power. We are planning to
develop an automated regularization strategy, in line with the
aMAT method13, to select the best possible trade-off between
univariate and current multivariate methods, to further improve
power of the multivariate analysis. Further, due to practical
limitations, we performed simulations of up to a hundred fea-
tures, leaving validation of the MOSTest procedure when
including more features as future work. Enabling the MOSTest
procedure, and particularly its genotype permutation scheme, in a
meta-analytical setting is a subject of future work.
The MOSTest method has several limitations. First, as with
several other multivariate methods, it only provides a p-value, but
does not provide the effect direction, limiting the application of
several post-GWAS tools. Second, currently, MOSTest requires
the availability of raw genotype data. Third, while discrete phe-
notypes will turn into continuous scales after pre-residualization
and inverse-normal transformation, we have not formally vali-
dated whether MOSTest is applicable to case/control traits.
Removing these limitations is also a subject of future work.
With the large gain of power and consequently lower required
sample sizes of MOSTest, we predict that it will be possible to
uncover the majority of SNPs influencing brain morphology in
the upcoming years. The UKB initiative, for instance, is set to
release neuroimaging data of a 100,000 individuals by 202225,
which we estimate will enable MOSTest to identify SNPs that
explain about 40% of the additive genetic variance in regional
brain morphology. MOSTest is well-suited as an exploratory tool,
followed up by studies that investigate the relation between the set
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of discovered loci and individual features, with a much decreased
multiple-comparisons burden. The MOSTest code is user friendly
and publicly available, see the Supplementary Materials. In
addition to brain structure, the MOSTest approach may also be of
value in uncovering the genetic determinants of brain function
and other complex human phenotypes consisting of correlated
component measures, such as mental, cognitive, or cardiometa-
bolic phenotypes, by taking advantage of the rich multivariate
data sets now available.
Methods
Sample. We made use of data from participants of the UKB population cohort,
obtained from the data repository under accession number 27412. The composi-
tion, set-up, and data gathering protocols of the UKB have been extensively
described elsewhere26. For this study, we selected individuals that had undergone
the neuroimaging protocol and had White European ancestry, as determined by a
combination of self-identification as “White British” and similar genetic ancestry
based on genetic principal components. For the primary analysis, making use of T1
MRI scan data released up to April 2019, we excluded 1094 individuals with a
primary or secondary ICD10 diagnosis of a neurological or mental disorder, as well
as 594 individuals with bad structural scan quality as indicated by an age and sex-
adjusted Euler number27 more than three standard deviations lower than the
scanner site mean. Our sample size for this analysis was n= 26,502, with a mean
age of 55.51 years (SD= 7.42). 51.97% of the sample was female. For the repli-
cation analyses, we made use of an additional neuroimaging batch released in
September 2019. After identical preprocessing steps as the primary sample, this
sample consisted of 4884 individuals with a mean age of 55.47 years (SD= 7.37),
52.42% was female.
Data preprocessing. T1-weighted scans were collected from three scanning sites
throughout the United Kingdom, all on identically configured Siemens Skyra 3T
scanners, with 32-channel receive head coils. The UKB core neuroimaging team
has published extensive information on the applied scanning protocols and pro-
cedures, which we refer to for more details25. The T1 scans were obtained from the
UKB data repositories and stored locally at the secure computing cluster of the
University of Oslo. We applied the standard “recon-all -all” processing pipeline of
Freesurfer v5.3, performing automated surface-based morphometry and subcortical
segmentation28,29. From the output, we extracted the sets of regional subcortical
and cortical morphology measures, as well as estimated intracranial volume
(eICV). Supplementary Table 1 contains all the regional morphology measures, per
subset, included in the current study. For each of these, we included both the left
and right hemisphere measure, if applicable.
We subsequently regressed out age, sex, scanner site, Euler number, and the first
20 genetic principal components from each measure. We further regressed out a
global measure specific to each of the feature subsets: eICV for the subcortical
volumes, mean thickness for the regional thickness measures, and total surface area
for the regional surface area measures. This was done to ensure we are studying the
genetic determinants of regional brain morphology rather than global effects.
Following this, we applied rank-based inverse-normal transformation30 to the
residuals of each measure: : y0i ¼ Φ1 ricN2cþ1
 
, where ri is the ordinary rank of the
measure for ith individual, N gives the sample size, Φ−1 denotes the standard
normal quantile, y0i is the value after transformation, and c= 0.5. This leads to
normally distributed input into the univariate GWAS. See Supplementary Fig. 12
and the associated text for a more in-depth discussion of the importance of this
normalization procedure.
Univariate GWAS procedure. We made use of the UKB v3 imputed data, which
has undergone extensive quality control procedures as described by the UKB
genetics team31. After converting the BGEN format to PLINK binary format, we
additionally carried out standard quality check procedures, including filtering out
individuals with more than 10% missingness, SNPs with more than 5% missing-
ness, and SNPs failing the Hardy–Weinberg equilibrium test at p= 1 × 10−9. We
further set a minor allele frequency threshold of 0.005, leaving 7,428,630 SNPs.
The univariate GWAS on each of the 171 pre-residualized and normalized regional
brain morphology measures were carried out using the standard additive model of
linear association between genotype vector, gj, and phenotype vector, y. Statistical
significance was assessed from Pearson’s correlation coefficient rj= corr(y, gj), as
implemented in MATLAB’s corr function. This is equivalent to testing significance of
the regression slope, bβj , as both bβj and rj are assumed to be t-distributed and have the
same t-value: tj ¼ βj=se βj
 
¼ rj=seðrjÞ ¼ rj
ffiffiffiffiffiffiffiffiffiffiffiffi




, and therefore the
same p-value, equal to Student’s t-cumulative distribution function (cdf) with N−2
degrees of freedom: Pval;j ¼ 2tcdfð tj

;N  2Þ, where N is the sample size16. Further,
we validated that the above procedure produces the same results as the association test
implemented in the commonly used PLINK’s additive model, option plink
--assoc.
Independent significant SNPs and genomic loci were identified in accordance
with FUMA SNP2GENE definition21. First, we select a subset of SNPs that pass
genome-wide significance threshold 5 × 10−8 (calculated by min-P or MOSTest),
and use PLINK to perform a clumping procedure at LD r2= 0.6, to identify the list
of independent significant SNPs. Second, we clump the list of independent
significant SNPs at LD r2= 0.1 threshold to identify lead SNPs. Third, we query the
reference panel for all candidate SNPs in LD r2 of 0.1 or higher with any lead SNPs.
Further, for each lead SNP, it’s corresponding genomic locus is defined as a
contiguous region of the lead SNPs’ chromosome, containing all candidate SNPs in
r2= 0.1 or higher LD with the lead SNP. Finally, adjacent genomic loci are merged
together if they are separated by <250 Kb. Allele LD correlations are computed
from EUR population of the 1000 genomes Phase 3 data.
MOSTest procedure. Let zij be the value of signed test statistic (z-score) calculated
from the univariate association test between jth SNP and ith phenotype. Let zj=
(z1j, …, zKj) be the vector of z-scores of jth SNP across K phenotypes. Let Z= {zij}
be the matrix of z-scores, with rows corresponding to SNPs, and columns corre-
sponding to phenotypes. Further, let eZ ¼ ezij
n o
be the matrix of z-scores, calcu-
lated from association tests on a randomly permuted genotype vector of each SNP.
To preserve correlation structure among phenotypes, the permutation was per-
formed only once for each SNP, and the resulting genotype vector was used in
association test across all phenotypes.
The MOSTest test statistic, X2j , for the jth SNP is calculated as Mahalanobis
norm X2j ¼ zTj eR1zj , where eR is the K-by-K correlation matrix of eZ. The null
hypothesis of the MOSTest is that zj is distributed as a multivariate normal random
variable with zero mean and covariance eR. To compute the theoretical (i.e., under
null) p-value of the MOSTest test statistic, we calculated the tail probability that a
Chi-square statistic exceeds X2j . This probability is given by chi-square distribution
with K degrees of freedom, or, equivalently, a gamma distribution, gamma(K/2,2)32.
Instead of using theoretical values, we fit the two free parameters of the gamma(a, b)
distribution to the observed distribution of X2j under permutation (shown in
Supplementary Table S4). The p-value of the MOSTest test statistic is then obtained
from a cumulative distribution function of the gamma distribution,
pMOST ¼ CDFgamma a;bð ÞðzTj eR1zjÞ. To clarify our notation, gamma(a, b) distribution
is parametrized by shape (a) and scale (b), so that pgamma xja; bð Þ ¼ 1baΓðaÞ xa1e
x
b ,
where Γ(·) is the gamma function.
In the simulation scenarios with regularization, the correlation matrix eR matrix
was replaced with its regularized version eR0 ¼ US0rUT , where USUT ¼ eR is an SVD
decomposition of eR, and the diagonal matrix S0r was obtained from S by replacing r
smallest eigenvalues with the next smallest eigenvalue; r is an integer parameter
that runs from 0 (no regularization) to K-1 (full regularization).
Controlling for covariates, such as genetic principal components, is done via
pre-residualization of all phenotype vectors, i.e., we replace them with the
corresponding residual after multiple linear regression of the phenotype vector on
the covariates. In addition, we perform a rank-based inverse-normal
transformation of the residualized phenotypes, to ensure that z-scores forming the
input to MOSTest are normally distributed.
MOSTest code is publicly available: https://github.com/precimed/mostest.
MiXeR analysis. We applied a causal mixture model6,16 to estimate the percentage
of variance explained by genome-wide significant SNPs as a function of sample
size. For each SNP, i, MiXeR models its additive genetic effect of allele substitution,
βi, as a point-normal mixture, βi ¼ 1 π1ð ÞN 0; 0ð Þ þ π1Nð0; σ2βÞ, where π1
represents the proportion of non-null SNPs (polygenicity) and σ2β represents var-
iance of effect sizes of non-null SNPs (discoverability). Then, for each SNP, j,
MiXeR incorporates LD information and allele frequencies for 9,997,231 SNPs
extracted from 1000 Genomes Phase 3 data to estimate the expected probability






rijβi þ ϵj , where N
is sample size, Hi indicates heterozygosity of ith SNP, rij indicates allelic correlation
between ith and jth SNPs, and ϵj  Nð0; σ20Þ is the residual variance. Further, the




0, are fitted by direct maximization of the likelihood
function. Fitting the univariate MiXeR model does not depend on the sign of zj,
allowing us to calculate jzjj from MOSTest p-values, zj

 ¼ jF1 pj=2
 
j, where F−1
is the inverse function of the standard normal c.d.f., and pj is p-value from
MOSTest. Finally, given the estimated parameters of the model, the power curve S
(N) is then calculated from the posterior distribution p(δj|zj, N).
Gene-set analyses. We made use of the Functional Mapping and Annotation of
GWAS (FUMA) online platform (https://fuma.ctglab.nl/) to further process the
output from MOSTest and min-P. Through FUMA, we carried out MAGMA-
based gene analyses using default settings, which entail the application of a SNP-
wide mean model and use of the 1000 Genomes Phase 3 EUR reference panel.
Gene-set analyses were done in a similar manner, restricting the sets under
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investigation to those that are part of the Gene Ontology biological processes subset
(n= 4436), as listed in the Molecular Signatures Database (MsigdB) v5.2.
Simulations. In our simulations, we used the same panel of N= 26,502 individuals
andM= 7,428,630 markers as in our main analysis. Using a simple additive genetic
model, we drew genetic effects β from a certain distribution, and then calculated
quantitative phenotypes yk of the kth sample as yk ¼
PM
j¼1 gkjβj þ ϵk , where G=
(gkj) is an N by M genotype matrix, containing the number of reference alleles for
the kth sample and jth variant. Here, βj is the causal effect size, and ϵ is a normally
distributed residual, drawn from a normal distribution with zero mean and variance
set in a way that yields the pre-defined level of heritability, h2=Var(Gβ)/Var(y).
The computations were performed using publicly available tools (https://github.
com/precimed/simu).
To generate the vector of genetic effects, β, we randomly drew a certain number
(typically nc= 100) of “causal” variants from chromosome 21 (containing 102,079
SNPs). The genetic effect sizes of all other variants were set to zero. Under the
assumption of negligible linkage disequilibrium across chromosomes, this design
allowed us to validate a uniform p-value distribution under null (i.e., on all
chromosomes except chromosome 21), thus confirming a correct type-I error. In
addition, we validated the type-I error under the genotype permutation scheme
employed by the MOSTest procedure. Across causal variants, the β values were
drawn either from a normal distribution, or from a standard Cauchy distribution.
The default settings, particularly nc= 100 and h2= 0.004, were chosen to simulate
a realistic magnitude of the genetic effects, with h2= 29.1% heritability and nc=
7.3 K causal variants genome-wide, if all chromosomes would have been allowed to
have genetic effects.
To simulate a realistic multivariate scenario with genetic and phenotypic
correlation across up to T= 25 features, we introduced covariance structure both
in β and in ϵ, independently set either to an identity matrix (no correlation) or to
the correlation matrix of the first T subcortical volumes, as defined in our main
analysis. Further, for each causal genetic variant, we vary the number of non-
zero effects across features, t, ranging from t= 1 (sparse effects scenario), to t=
T (distributed effects scenario). In the sparse cases, t < T, we increased the total
number of causal variants proportionally to the ratio of T/t, and ensured that
each trait had exactly the pre-defined number of causal variants, while each
causal variant, on average, contributed to t out of T traits.
We applied the link function to generate non-normally distributed phenotypes
with heavy tails, yielding y ¼ f ðGβþ ϵÞ, where f can be either identity, f(x)= x, or
an exponent f(x)= ex. To simulate strict linear dependency between features (i.e., a
rank-deficient covariance matrix), we replaced the set of T features, calculated as
y ¼ Gβþ ϵ, with a set of T(T− 1)/2 features, formed by all pairwise combinations.
We then applied the link function f (identity or an exponent).
A detailed list of simulation parameters and scenarios is specified in
Supplementary Tables 4 and 5. Each simulation scenario was performed ten times,
each with random selection of causal variants, and randomly drawn β and ϵ.
Finally, we executed MQFAM, MultiPhen and MultiABEL according to
guidelines provided by the original software. A typical simulation result of a
single run visualizes type-I error under null, type-I error under permutations,
statistical power to detect non-null association at causal variants, and
corresponding quantile–quantile plots (on chromosome 21, under null, and
under permutations). Full simulation scripts are available at https://github.com/
precimed/mostest
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The data incorporated in this work were gathered from the public UK Biobank resource.
The generated GWAS summary statistics can be fetched from https://archive.sigma2.no/
pages/public/datasetDetail.jsf?id=10.11582/2020.00031.
Code availability
The code is available via https://github.com/precimed/mostest (GPLv3 license).
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